id,agency_id,docket_id,title,document_type,subtype,posted_date,posted_year,posted_month,comment_start_date,comment_end_date,last_modified,fr_doc_num,open_for_comment,withdrawn,object_id
FDA-2015-D-4386-0010,FDA,FDA-2015-D-4386,"Deviation Reporting for Human Cells, Tissues, and Cellular and Tissue-Based Products; Guidance for Industry; Availability",Notice,Notice of Availability,2017-09-07T04:00:00Z,2017,9,2017-09-07T04:00:00Z,,2017-09-07T13:48:59Z,2017-18737,0,0,0900006482b131fd
FDA-2015-D-4386-0011,FDA,FDA-2015-D-4386,"Deviation Reporting for Human Cells, Tissues, and Cellular and Tissue-Based Products Regulated Solely Under Section 361 of the Public Health Service Act and 21 CFR Part 1271 Guidance for Industry",Other,Guidance,2017-09-07T04:00:00Z,2017,9,2017-09-07T04:00:00Z,,2024-11-07T01:11:02Z,,1,0,0900006482b13dfd
FDA-2015-D-4386-0002,FDA,FDA-2015-D-4386,"Draft Guidance for Industry Deviation Reporting for Human Cells, Tissues, and Cellular and Tissue-Based Products Regulated Solely Under Section 361 of the Public Health Service Act and 21 CFR Part 1271",Other,Guidance,2015-12-24T05:00:00Z,2015,12,2015-12-24T05:00:00Z,,2024-11-11T21:17:36Z,,1,0,0900006481dd0460
FDA-2015-D-4386-0001,FDA,FDA-2015-D-4386,"Deviation Reporting for Human Cells, Tissues, and Cellular and Tissue-Based Products; Draft Guidance for Industry; Availability",Notice,Notice of Availability,2015-12-24T05:00:00Z,2015,12,2015-12-24T05:00:00Z,2016-03-24T03:59:59Z,2016-03-22T18:00:26Z,2015-32323,0,0,0900006481dd00d7